晚发性多发性硬化的临床特征与长期结局:一项瑞典全国性研究
晚发性组原发进展型比例更高(25.2% vs 4.5%),DMT使用更少(74.7% vs 95.6%),高效DMT暴露更低(45.8% vs 73.5%),达到EDSS 4和6的风险更高(aHR分别为2.71和2.67)。
要点
- 晚发性多发性硬化占11.8%,原发进展型比例高于成人发病(25.2% vs 4.5%)。
- 晚发性组DMT使用率更低(74.7% vs 95.6%),高效DMT暴露更少(45.8% vs 73.5%)。
- 晚发性组达到EDSS 4和6的风险更高(aHR 2.71和2.67)。
核心结论
- 晚发性多发性硬化患者是特别脆弱的群体,临床应密切监测,需进一步研究评估老年多发性硬化患者使用DMT的获益。
研究设计与样本
- 瑞典全国性多发性硬化登记研究,纳入2001年1月1日至2018年12月31日发病、年龄≥18岁且有≥2次EDSS记录的患者共8739例。
主要发现
- 晚发性组1028例(11.8%),原发进展型比例高于成人发病组(25.2% vs 4.5%,p < 0.001)。
- 晚发性组DMT使用率低于成人发病组(74.7% vs 95.6%,p < 0.001)。
- 晚发性组高效DMT暴露比例低于成人发病组(45.8% vs 73.5%,p < 0.001)。
- 晚发性组达到EDSS 4的风险高于成人发病组(aHR 2.71,95% CI 2.22-3.30,p < 0.001)。
- 晚发性组达到EDSS 6的风险高于成人发病组(aHR 2.67,95% CI 2.12-3.36,p < 0.001)。
临床怎么用
- 作者认为晚发性多发性硬化是特别脆弱的群体,临床支持密切监测这些患者;需进一步研究评估老年多发性硬化患者使用DMT的获益。
局限性
- 需进一步研究评估和阐明老年多发性硬化患者使用DMT的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Clinical onset of multiple sclerosis (MS) after the age of 50 years is uncommon and associated with a less favorable natural history. The differences in long-term outcomes in patients with late-onset MS (LOMS, onset 50 years or older) and adult-onset MS (AOMS, onset 18 years or older and younger than 50 years) during the disease-modifying therapy (DMT) era have been less studied. This study aimed to compare patient characteristics, DMT exposure, and disability progression in Swedish patients with LOMS and AOMS over 2 decades (2001-2022). METHODS: The nationwide Swedish MS registry was searched for patients with an onset of MS between January 1, 2001, and December 31, 2018, with symptom onset at age 18 years or older and ≥2 recorded Expanded Disability Status Scale (EDSS) scores. Clinical and demographic parameters and exposure to DMT were compared between LOMS and AOMS. Time to disability milestones (EDSS 4 and 6) was assessed using Kaplan-Meier curves and Cox proportional hazards regression models adjusted for sex, disease course, calendar year at onset, and DMT exposure. RESULTS: Among 8739 patients with MS who met inclusion criteria, 1,028 (11.8%) were LOMS. Primary progressive MS was more frequently diagnosed in LOMS compared with that in AOMS (25.2% vs 4.5%; p < 0.001). Most of the patients had been prescribed DMT, but more rarely in LOMS compared with AOMS (74.7% vs 95.6%; p < 0.001). Less than half of patients with LOMS had been exposed to a high-efficacy DMT (45.8%) compared with 73.5% of AOMS (p < 0.001). The risk of reaching disability milestones was greater for LOMS compared with that for AOMS (EDSS 4; adjusted hazard ratio [aHR] 2.71; 95% CI 2.22-3.30; p < 0.001, and EDSS 6; aHR 2.67; 95% CI 2.12-3.36; p < 0.001). DISCUSSION: This study distinguishes LOMS as a particularly vulnerable group and clinically supports close vigilance of these patients. Further studies are needed to assess and clarify the benefit of DMT usage in older adults with MS.
引用
- Mouresan EF, Mentesidou E, Berglund A, et al. Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study. Neurology. 2024. PMID: 38394472. doi:10.1212/WNL.0000000000208051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。